Our executive leaders discuss the benefits of a shared leadership model and the experience they each bring to Race Oncology.
Race Oncology is please update our shareholders on the clinical progress of bisantrene. This talk was presented by Race Oncology’s CSO Dr Daniel Tillett at the IRD Invest virtual conference on the 29th July 2019.
Overview of Race Oncology’s new “5 path” strategy for the development of Bisantrene. 0.00 – 10.00 • Introduction & welcome | Mr Peter Molloy CEO/MD 10.00 – 39.01 • Race’s 5 Path strategy | Dr Daniel Tillett CSO 39.01 –…
What is Bisantrene and where did it come from? Click here to watch CEO Peter Molloy’s interview on Edison TV.
A Perth family tells the story of their son’s battle with Acute Myeloid Leukaemia. When Kai got sick, they searched the world for answers.
Race Oncology Limited (RAC) is pleased to announce it has produced its first good manufacturing practice (GMP) batch of cancer drug Bisantrene. The first batch will be enough to treat up to sixty patients, with a further four batches scheduled to…
In November 2017, Race CEO Peter Molloy spoke to investors in London at the Biotech & Money conference.